Oruka Therapeutics, Inc. (ORKA) Stock Price & Analysis

Oruka Therapeutics, Inc. (ORKA) rose 1.67% to USD 92.51 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.

ORKA last closed at USD 90.99; the session ranged USD 89.75–93.98 on volume of 600,471 shares. Market capitalization is $6.13B, with a 52-week range of USD 14.67–115.52 (NGM). Source: Nexqual, September 8, 2026 at 05:44 UTC.

Key Statistics (as of September 8, 2026 at 05:44 UTC)

Technical Analysis (ORKA)

Nexqual's technical model rates ORKA "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.

Analyst Ratings (ORKA)

Wall Street analysts rate ORKA "Strong Buy" based on 12 analysts, with a mean price target of USD 155 (range USD 117–200), per Nexqual as of September 8, 2026 at 05:44 UTC.

Earnings (ORKA)

Recent Earnings History

Source: Nexqual, September 8, 2026 at 05:44 UTC.

Financials & Fundamentals (ORKA)

Source: Nexqual, September 8, 2026 at 05:44 UTC.

Financial Health Score (ORKA)

Nexqual rates Oruka Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 05:44 UTC.

Ownership (ORKA)

Source: Nexqual, September 8, 2026 at 05:44 UTC.

Leadership (ORKA)

Oruka Therapeutics, Inc. is led by Lawrence Otto Klein (age 42), President, CEO & Director, per Nexqual as of September 8, 2026 at 05:44 UTC.

Major Backers & Investors (ORKA)

Notable institutional backers of Oruka Therapeutics, Inc. include FMR, LLC, Venrock Adviser, LLC, Fairmount Funds Management LLC, according to Nexqual as of September 8, 2026 at 05:44 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, September 8, 2026 at 05:44 UTC.

From Oruka Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We and Paragon have also filed, and may continue to file, patent applications relating to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods of use, including for ORKA-002.   We hold exclusive rights to ORKA-001 and ORKA-002, as well as the associated IL-23 and IL-17 patent rights, pursuant to license agreements with Paragon.
• Our strategy is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological risk.
• We believe this approach will enable us to improve meaningfully upon the efficacy and convenience of standard-of-care medicines while significantly reducing technical and biological risk.

Partnerships

• In September 2024, we exercised our exclusive option to acquire certain rights to ORKA-001, and in December 2024, we entered into a corresponding license agreement with Paragon pursuant to which Paragon granted us a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23 in all fields other than the field of inflammatory bowel disease.
• As of December 31, 2025, we have not entered into a license agreement with Paragon and Paruka related to this additional option agreement.   15     Cell Line License Agreement   In March 2024, we entered into the Cell Line License Agreement (the "Cell Line License Agreement") with WuXi Biologics Ireland Limited ("WuXi Biologics").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.